Biomaterials

Biography

Andrew is Director of R&D in Innovation at BTG. He specialises in the development of advanced biomedical polymer systems, for instance, to enhance the biocompatibility of implants or to modulate delivery of active agents in the body. These technologies have been applied to novel drug-device combination products for use in interventional therapies in the treatment of cardiovascular disease and cancer. He has published ~200 papers (H-index 46), 11 book chapters and 50 patent families/applications in the fields of polymers, biomaterials and drug delivery. He was recently awarded the Chapman Medal for distinguished research in the field of biomedical materials.

Abstract

Abstract : Particulate embolization agents: Impact of biomaterial physicochemical properties on clinical performance